Background: Cancer care is evolving rapidly, and costs and value of new treatments are frequently debated. Up-to-date evidence on the total cost of cancer is needed to inform policy decisions. This study estimates the cost of cancer in Europe in 2018 and extends a previous analysis for 1995-2014.
Methods: Cancer-specific health expenditure were derived from national estimates. Data on cancer drug sales were obtained from IQVIA. The productivity loss from premature mortality was estimated from data from Eurostat and the World Health Organization. Estimates of the productivity loss from morbidity and informal care costs were based on previous studies.
Findings: The total cost of cancer was €199 billion in Europe (EU-27 plus Iceland, Norway, Switzerland, and the United Kingdom) in 2018. Total costs ranged from €160 per capita in Romania to €578 in Switzerland (after adjustment for price differentials). Health expenditure on cancer care were €103 billion, of which €32 billion were spent on cancer drugs. Informal care costs were €26 billion. The total productivity loss was €70 billion, composed of €50 billion from premature mortality and €20 billion from morbidity.
Interpretation: Health expenditure on cancer care were of a similar magnitude as the sum of non-health-care costs in 2018. Over the last two decades, health spending on cancer has increased faster than the increase in cancer incidence. The productivity loss from premature mortality has decreased because of reductions in mortality in the working-age population. Trends in informal care costs and productivity loss from morbidity are uncertain because of lack of comparable data.
Keywords: Cancer; Cancer drugs; Europe; Health expenditure; Productivity loss.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest statement T.H. and P.L. are employed at IHE, an independent research organization receiving funding from both public and private sector organizations. B.J. reports personal fees from BMS, Celgene, Janssen, Novartis, and Roche and N.W. from Janssen, MSD, Novartis, and Oasmia for participation in advisory boards and educational activities outside the submitted work.
Economic burden of malignant blood disorders across Europe: a population-based cost analysis.Lancet Haematol. 2016 Aug;3(8):e362-70. doi: 10.1016/S2352-3026(16)30062-X. Epub 2016 Jul 22. Lancet Haematol. 2016. PMID: 27476787
Cost of disorders of the brain in Europe 2010.Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79. doi: 10.1016/j.euroneuro.2011.08.008. Epub 2011 Sep 15. Eur Neuropsychopharmacol. 2011. PMID: 21924589
The cost and burden of cancer in the European Union 1995-2014.Eur J Cancer. 2016 Oct;66:162-70. doi: 10.1016/j.ejca.2016.06.022. Epub 2016 Aug 31. Eur J Cancer. 2016. PMID: 27589247
The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.Tob Use Insights. 2015 Jul 14;8:1-35. doi: 10.4137/TUI.S15628. eCollection 2015. Tob Use Insights. 2015. PMID: 26242225 Free PMC article. Review.
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.